Antihypertensive Mechanisms of Minocycline in Resistant Hypertension
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-100
SponsorUniversity of Florida
About this trial
The goal of this clinical trial is to learn about the mechanisms by which minocycline effect blood pressure in individuals with treatment-resistant hypertension. The main questions it aims to answer are:
* To what extent does minocycline lower blood pressure? * Are such blood pressure effects mediated through changes in gut microbiota, gut leakiness, systemic inflammation, neuroinflammation, or some combination of these?
Participants will be randomly assigned to treatment with minocycline or placebo, treated daily for 3 months, to evaluate these questions.
Eligibility criteria
Qualifiers
Age ≥18 years
Uncontrolled TRH, defined as uncontrolled blood pressure (mean 24-hour ambulatory systolic BP ≥125 mm Hg or diastolic BP ≥80 mm Hg) while being adherent to a stable (no changes in ≥14 days prior) antihypertensive regimen of 3 or more drugs, including an adequately dosed diuretic or unable to tolerate a diuretic.
The participant agrees to have all study procedures performed
Disqualifiers
Known hypersensitivity or contraindication to minocycline or other tetracyclines
Recent (≤3 months prior), ongoing, or expected use of oral antibiotics
Estimated glomerular filtration rate (eGFR) of <45mL/min/1.73m2, using the MDRD equation
Known secondary hypertension
Trial design
Treatments tested in this trial
- Minocycline Hydrochloride
- Placebo
Treatment groups
120 Participants
are divided into 2 treatment groupsSponsors and collaborators
University of Florida
Lead sponsor
Emory University
Collaborator
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator
Source ClinicalTrials.gov